Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
TAK 
Takeda Pharmaceutical Co Ltd ADR (TAK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: TAK (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 8.46% | Avg. Invested days 34 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 46.98B USD | Price to earnings Ratio 34.58 | 1Y Target Price 16.76 |
Price to earnings Ratio 34.58 | 1Y Target Price 16.76 | ||
Volume (30-day avg) 1553033 | Beta 0.41 | 52 Weeks Range 12.29 - 15.30 | Updated Date 03/31/2025 |
52 Weeks Range 12.29 - 15.30 | Updated Date 03/31/2025 | ||
Dividends yield (FY) 4.39% | Basic EPS (TTM) 0.43 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 4.54% | Operating Margin (TTM) 0.53% |
Management Effectiveness
Return on Assets (TTM) 2.51% | Return on Equity (TTM) 2.94% |
Valuation
Trailing PE 34.58 | Forward PE 38.02 | Enterprise Value 75413475824 | Price to Sales(TTM) 0.01 |
Enterprise Value 75413475824 | Price to Sales(TTM) 0.01 | ||
Enterprise Value to Revenue 2.46 | Enterprise Value to EBITDA 10.26 | Shares Outstanding 3159600128 | Shares Floating 1584180586 |
Shares Outstanding 3159600128 | Shares Floating 1584180586 | ||
Percent Insiders 0.01 | Percent Institutions 2.33 |
Analyst Ratings
Rating 4.5 | Target Price 15.72 | Buy - | Strong Buy 3 |
Buy - | Strong Buy 3 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Takeda Pharmaceutical Co Ltd ADR
Company Overview
History and Background
Takeda Pharmaceutical Company Limited was founded in 1781 in Osaka, Japan. Initially a medicine wholesaler, it evolved into a research-based pharmaceutical company, expanding globally through strategic acquisitions and focusing on innovative therapies.
Core Business Areas
- Gastroenterology: Focuses on developing treatments for gastrointestinal diseases like inflammatory bowel disease (IBD) and short bowel syndrome (SBS).
- Rare Diseases: Addresses rare genetic and hematologic disorders, including hemophilia and hereditary angioedema.
- Plasma-Derived Therapies (PDT) Immunology: Creates therapies derived from human plasma to treat immune deficiencies, autoimmune diseases, and other conditions.
- Oncology: Develops and markets cancer therapies, including targeted therapies and immunotherapies, in areas like hematologic malignancies and solid tumors.
- Neuroscience: Researches and develops treatments for neurological and psychiatric disorders, such as ADHD, depression, and narcolepsy.
Leadership and Structure
The company is led by Christophe Weber (President and CEO). The organizational structure involves a global matrix with business units focused on therapeutic areas and regional operations ensuring localized strategies and execution.
Top Products and Market Share
Key Offerings
- Entyvio (vedolizumab): An integrin receptor antagonist used to treat ulcerative colitis and Crohn's disease. It faces competition from Humira (AbbVie), Remicade (Janssen), and Stelara (Janssen). Market share data unavailable. Revenue approximately $5.2 billion in FY2023.
- Takhzyro (lanadelumab): A monoclonal antibody used for the prevention of hereditary angioedema attacks. Competitors include Orladeyo (BioCryst) and Berinert (CSL Behring). Market share data unavailable. Revenue approximately $742 million in FY2023.
- Adcetris (brentuximab vedotin): An antibody-drug conjugate used in the treatment of Hodgkin lymphoma and other lymphomas. Competitors include lymphoma treatments from Roche/Genentech and Bristol Myers Squibb. Revenue approximately $868 million in FY2023.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and increasing competition from generic and biosimilar drugs. Growth is driven by an aging global population, rising prevalence of chronic diseases, and advancements in biotechnology.
Positioning
Takeda is a global biopharmaceutical company with a strong focus on innovative therapies and emerging markets. Its competitive advantages include a diverse portfolio of products, a strong R&D pipeline, and a global presence. Takeda's strong research pipeline keeps it competitive in a global industry.
Total Addressable Market (TAM)
The global pharmaceuticals market is estimated to be approximately $1.4 trillion USD. Takeda is positioned to capture a significant share of this market through its focused therapeutic areas and innovative product pipeline.
Upturn SWOT Analysis
Strengths
- Strong global presence
- Diverse product portfolio
- Robust R&D pipeline
- Focus on innovative therapies
- Experience and expertise in biopharmaceuticals
Weaknesses
- High debt levels due to Shire acquisition
- Exposure to generic competition
- Reliance on key products
- Integration challenges post-acquisition
- Stringent regulatory requirements
Opportunities
- Expanding into emerging markets
- Developing novel therapies for unmet medical needs
- Strategic collaborations and partnerships
- Leveraging digital technologies in healthcare
- Personalized medicine.
Threats
- Increasing generic and biosimilar competition
- Pricing pressures and healthcare reforms
- Regulatory hurdles and delays
- Product liability risks
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- JNJ
- MRK
- PFE
- NVS
- ABBV
Competitive Landscape
Takeda competes with major global pharmaceutical companies in various therapeutic areas. It holds a competitive advantage in certain niche markets, but faces intense competition from larger players with greater resources.
Major Acquisitions
Shire
- Year: 2019
- Acquisition Price (USD millions): 62000
- Strategic Rationale: Acquisition of Shire expanded Takeda's portfolio in rare diseases, gastroenterology, and neuroscience, enhancing its global presence and pipeline.
Growth Trajectory and Initiatives
Historical Growth: Takeda's historical growth has been driven by organic growth of key products, strategic acquisitions (most notably Shire), and expansion into emerging markets.
Future Projections: Future growth projections are based on analyst estimates. Growth expectations are modest and will depend on new product launches and pipeline progress, estimated around 3-5% annually.
Recent Initiatives: Recent initiatives include focusing on key therapeutic areas, streamlining operations, investing in R&D, and strengthening its presence in emerging markets.
Summary
Takeda is a globally present pharmaceutical company with a diverse product portfolio. It needs to reduce debt from the Shire acquisition and carefully watch out for emerging competition, but is well-positioned in key therapeutic areas with continued investment in research and development. Takeda is positioned to capture a good share of the market.
Similar Companies
- JNJ
- MRK
- PFE
- NVS
- ABBV
- LLY
- AZN
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
- Market research reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data are approximate and may vary by source. Financial data may be dated. The AI-based rating is based on a simplified analysis and should not be the sole basis for investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Takeda Pharmaceutical Co Ltd ADR
Exchange NYSE | Headquaters - | ||
IPO Launch date 2008-10-27 | President, CEO & Representative Director Mr. Christophe Weber | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 49281 | Website https://www.takeda.com |
Full time employees 49281 | Website https://www.takeda.com | ||
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.